Advertisement

Oily (Lipophilic) Solutions and Suspensions

  • Susan W. Larsen
  • Mette A. Thing
  • Claus Larsen
Chapter
Part of the Advances in Delivery Science and Technology book series (ADST)

Abstract

Formulation of drugs in the form of lipophilic solutions or suspensions may lead to a considerable prolongation of drug action following parenteral administration. The in vivo performance of such oil depot injectables are influenced by three major parameters, i.e., the rate of drug release from the oil vehicle, the degree of drug load, and the syringeability. Thus, the aim of this chapter is mainly to give a brief overview over various means to manipulate in vitro characteristics including (1) vehicle viscosity, (2) drug solubility in oil vehicles, and (3) drug partitioning between oil and aqueous buffer. Furthermore, the utility of in vitro release models in the design of lipophilic drug formulations and for quality control purposes is discussed.

Keywords

Drug Release Drug Load Ricinoleic Acid Isopropyl Myristate Mixture Viscosity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Berkland C, Pollauf E, Raman C, Silverman R, Kim K, Pack DW (2007) Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism. J Pharm Sci 96:1176–1191PubMedCrossRefGoogle Scholar
  2. 2.
    Larsen C, Larsen SW, Jensen H, Yaghmur A, Østergaard J (2009) Role of in vitro release models in formulation development and quality control of parenteral depots. Expert Opin Drug Deliv 6:1283–1295PubMedCrossRefGoogle Scholar
  3. 3.
    Metselaar JM, Storm G (2005) Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2:465–476PubMedCrossRefGoogle Scholar
  4. 4.
    Sinha VR, Trehan A (2005) Biodegradable microspheres for parenteral delivery. Crit Rev Ther Drug Carrier Syst 22:535–602PubMedGoogle Scholar
  5. 5.
    Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160PubMedCrossRefGoogle Scholar
  6. 6.
    Moghimi SM, Hamad I, Bunger R, Andresen TL, Jorgensen K, Hunter AC, Baranji L, Rosivall L, Szebeni J (2006) Activation of the human complement system by cholesterol-rich and pegylated liposomes – modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16:167–174CrossRefGoogle Scholar
  7. 7.
    Sharma A, Sharma US (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123–140CrossRefGoogle Scholar
  8. 8.
    Freitas S, Merkle HP, Gander B (2005) Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313–332PubMedCrossRefGoogle Scholar
  9. 9.
    Jiang W, Gupta RK, Deshpande MC, Schwendeman SP (2005) Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391–410PubMedCrossRefGoogle Scholar
  10. 10.
    Larsen SW, Larsen C (2009) Critical factors influencing the in vivo performance of long acting lipophilic solutions – impact on in vitro release method design. AAPS J 2:762–770CrossRefGoogle Scholar
  11. 11.
    Murdan S, Florence AT (2000) Non-aqueous solutions and suspensions as sustained-release injectable formulations. In: Senior J, Radomsky M (eds) Sustained-release injectable products. Interpharm, Denver, pp 71–107Google Scholar
  12. 12.
    Chien YW (1981) Long acting parenteral drug formulations. J Parenter Sci Technol 35:106–139PubMedGoogle Scholar
  13. 13.
    Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47:741–773PubMedCrossRefGoogle Scholar
  14. 14.
    Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10:315–333PubMedCrossRefGoogle Scholar
  15. 15.
    Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331PubMedGoogle Scholar
  16. 16.
    Dreyfuss J, Shaw JM, Ross JJ (1976) Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow-release characteristics in dogs. J Pharm Sci 65:1310–1315PubMedCrossRefGoogle Scholar
  17. 17.
    Dreyfuss J, Ross JJ, Shaw JM, Miller I, Schreiber EC (1976) Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs. J Pharm Sci 65:502–507PubMedCrossRefGoogle Scholar
  18. 18.
    Luo JP, Hubbard JW, Midha KK (1997) Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. Pharm Res 14:1079–1084PubMedCrossRefGoogle Scholar
  19. 19.
    Aaes-Jørgensen T (1989) Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatr 13:77–85CrossRefGoogle Scholar
  20. 20.
    Viala A, Ba B, Durand A, Gouezo F, Hou N, Jørgensen A (1988) Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 94:293–297PubMedCrossRefGoogle Scholar
  21. 21.
    Jørgensen A, Overø KF (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Acta Psychiatr Scand Suppl 279:41–54Google Scholar
  22. 22.
    Matsunaga Y, Nambu K, OH EY, Miyazaki H, Hashimoto M (1987) Absorption of intramuscularly administered [14C]haloperidol decanoate in rats. Eur J Drug Metab Pharmacokinet 12:175–181PubMedCrossRefGoogle Scholar
  23. 23.
    Wiles DH, McCreadie RG, Whitehead A (1990) Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Psychopharmacology 101:274–281PubMedCrossRefGoogle Scholar
  24. 24.
    Chang W, Lin S, Juang D, Chen L, Yang C, Hu W, Chien C, Lam YWF, Jann MW (1993) Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr Res 9:35–40PubMedCrossRefGoogle Scholar
  25. 25.
    Dexter MB, Shott MJ (1979) The evaluation of the force to expel oily injection vehicles from syringes. J Pharm Pharmacol 31:497–500PubMedCrossRefGoogle Scholar
  26. 26.
    Allahham A, Stewart P, Marriott J, Mainwaring DE (2004) Flow and injection characteristics of pharmaceutical parenteral formulations using a micro-capillary rheometer. Int J Pharm 270:139–148PubMedCrossRefGoogle Scholar
  27. 27.
    Irving JB (1977) Viscosities of binary liquid mixtures: the effectiveness of mixture equations. National Engineering Laboratory, East Kilbride, GlasgowGoogle Scholar
  28. 28.
    Irving JB (1977) Viscosity of binary liquid mixtures: a survey of mixture equations. National Engineering Laboratory, East Kilbride, GlasgowGoogle Scholar
  29. 29.
    Arrhenius S (1887) Über die innere Reibung verdünnter Wässeriger Lösungen. Z Phys Chem 1:285–298Google Scholar
  30. 30.
    Larsen DB, Fredholt K, Larsen C (2001) Addition of hydrogen bond donating excipients to oil solution: effect on in vitro drug release rate and viscosity. Eur J Pharm Sci 13:403–410PubMedCrossRefGoogle Scholar
  31. 31.
    Sims EE, Worthington HEC (1985) Formulation studies on certain oily injection products. Int J Pharm 24:287–296CrossRefGoogle Scholar
  32. 32.
    Schultz K (1997) Parenteral oily depot formulations. In vitro and in vivo characterisation. The Royal Danish School of Pharmacy, CopenhagenGoogle Scholar
  33. 33.
    Fredholt K, Larsen DH, Larsen C (2000) Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur J Pharm Sci 11:231–237PubMedCrossRefGoogle Scholar
  34. 34.
    Hirano K, Ichihashi T, Yamada H (1982) Studies on the absorption of practically water-insoluble drugs following injection V: subcutaneous absorption in rats from solutions in water immiscible oils. J Pharm Sci 71:495–500PubMedCrossRefGoogle Scholar
  35. 35.
    Hirano K, Ichihashi T, Yamada H (1981) Studies on the absorption of practically water-insoluble drugs following injection. I. Intramuscular absorption from water-immiscible oil solutions in rats. Chem Pharm Bull 29:519–531PubMedCrossRefGoogle Scholar
  36. 36.
    Yamaoka Y, Roberts RD, Stella VJ (1983) Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. J Pharm Sci 72:400–405PubMedCrossRefGoogle Scholar
  37. 37.
    Patrick AI, Beall HD, Gilroy P, Sloan KB (1997) Effect of vehicles on topical delivery of 5-fluorouracil (%FU) by 1-acyl-5FU prodrugs. Int J Pharm 154:39–48CrossRefGoogle Scholar
  38. 38.
    Malcolmson C, Satra C, Kantaria S, Sidhu A, Lawrence MJ (1998) Effect of oil on the level of solubilization of testosterone propionate into nonionic oil-in-water microemulsions. J Pharm Sci 87:109–116PubMedCrossRefGoogle Scholar
  39. 39.
    Larsen DB, Parshad H, Fredholt K, Larsen C (2002) Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. Int J Pharm 232:107–117PubMedCrossRefGoogle Scholar
  40. 40.
    Riffkin C, Huber RKCH (1964) Castor oil as a vehicle for parenteral administration of steorid hormones. J Pharm Sci 53:891–895PubMedCrossRefGoogle Scholar
  41. 41.
    Jumaa M, Müller BW (2001) Development of a novel parenteral formulation for tetrazepam using a lipid emulsion. Drug Dev Ind Pharm 27:1115–1121PubMedCrossRefGoogle Scholar
  42. 42.
    Christensen JO, Schultz K, Mollgaard B, Kristensen HG, Mullertz A (2004) Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci 23:287–296PubMedCrossRefGoogle Scholar
  43. 43.
    Nankervis R, Davis SS, Day NH, Shaw PN (1995) Effect of lipid vehicle on the intestinal lymphatic transport of isotretinoin in the rat. Int J Pharm 119:173–181CrossRefGoogle Scholar
  44. 44.
    Radd BL, Newman AC, Fegely BJ, Chrzanowski FA, Lichten JL, Walkling WD (1985) Development of haloperidol in oil injection formulations. J Parenter Sci Technol 39:48–51PubMedGoogle Scholar
  45. 45.
    Patton JS, Stone B, Papa C, Abramowitz R, Yalkowsky SH (1984) Solubility of fatty acids and other hydrophobic molecules in liquid trioleoylglycerol. J Lipid Res 25:189–197PubMedGoogle Scholar
  46. 46.
    Rane SS, Anderson BD (2008) What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Deliv Rev 60:638–656PubMedCrossRefGoogle Scholar
  47. 47.
    James KC, Nicholls PJ, Roberts M (1969) Biological half-lives of [4-14C]testosterone and some of its esters after injection into the rat. J Pharm Pharmacol 21:24–27PubMedCrossRefGoogle Scholar
  48. 48.
    Kumar R, Betageri GV, Gupta RB (1998) Partitioning of oxytetracycline between aqueous and organic solvents – effect of hydrogen bonding. Int J Pharm 166:37–44CrossRefGoogle Scholar
  49. 49.
    Larsen SW, Frost AB, Østergaard J, Marcher H, Larsen C (2008) On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur J Pharm Sci 34:37–44PubMedCrossRefGoogle Scholar
  50. 50.
    Jain N, Yalkowsky SH (2001) Estimation of the aqueous solubility I: application to organic nonelectrolytes. J Pharm Sci 90:234–252PubMedCrossRefGoogle Scholar
  51. 51.
    Collander R (1950) The distribution of organic compounds between iso-butanol and water. Acta Chem Scand 4:1085–1098CrossRefGoogle Scholar
  52. 52.
    Leo A, Hansch C (1971) Linear free-energy relationships between partitioning solvent systems. J Org Chem 36:1539–1544CrossRefGoogle Scholar
  53. 53.
    Larsen SW, Thomsen AE, Rinvar E, Friis GJ, Larsen C (2001) Effect of drug lipophilicity on in vitro release rate from oil vehicles using nicotinic acid esters as model prodrug derivatives. Int J Pharm 216:83–93PubMedCrossRefGoogle Scholar
  54. 54.
    Uppoor VR (2001) Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72:127–132PubMedCrossRefGoogle Scholar
  55. 55.
    Burgess DJ, Crommelin DJ, Hussain AS, Chen ML (2004) Assuring quality and performance of sustained and controlled released parenterals. Eur J Pharm Sci 21:679–690PubMedCrossRefGoogle Scholar
  56. 56.
    Burgess DJ, Hussain AS, Ingallinera TS, Chen ML (2002) Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 4:E7PubMedCrossRefGoogle Scholar
  57. 57.
    Larsen DB, Joergensen S, Olsen NV, Hansen SH, Larsen C (2002) In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. J Control Release 81:145–154PubMedCrossRefGoogle Scholar
  58. 58.
    Larsen SW, Østergaard J, Friberg-Johansen H, Jessen MN, Larsen C (2006) In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci 29:348–354PubMedCrossRefGoogle Scholar
  59. 59.
    Larsen SW, Jessen MN, Østergaard J, Larsen C (2008) Assessment of drug release from oil depot formulations using an in vitro model – potential applicability in accelerated release testing. Drug Dev Ind Pharm 34:297–304PubMedCrossRefGoogle Scholar
  60. 60.
    Larsen C, Østergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, Andersen PH (2008) Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci 97:4622–4654PubMedCrossRefGoogle Scholar
  61. 61.
    Wallis WJ, Simkin PA, Nelp WB (1987) Protein traffic in human synovial effusions. Arthritis Rheum 30:57–63PubMedCrossRefGoogle Scholar
  62. 62.
    Bauer W, Short CL, Bennett GA (1933) The manner of removal of proteins from normal joints. J Exp Med 57:419–433PubMedCrossRefGoogle Scholar
  63. 63.
    Simkin PA, Bassett JE, Koh EM (1995) Synovial perfusion in the human knee: a methodologic analysis. Semin Arthritis Rheum 25:56–66PubMedCrossRefGoogle Scholar
  64. 64.
    Simkin PA, Benedict RS (1990) Iodide and albumin kinetics in normal canine wrists and knees. Arthritis Rheum 33:73–79PubMedCrossRefGoogle Scholar
  65. 65.
    Akers MJ, Fites AL, Robison RL (1987) Formulation design and development of parenteral suspensions. J Parenter Sci Technol 41:88–96PubMedGoogle Scholar
  66. 66.
    Pedersen BT, Larsen SW, Østergaard J, Larsen C (2007) In vitro assessment of lidocaine release from aqueous and oil solutions and from preformed and in situ formed aqueous and oil suspensions. Parenteral depots for intra-articular administration. Drug Deliv 15:23–30CrossRefGoogle Scholar
  67. 67.
    Yu LX, Foster TP, Sarver RW, Moseley WM (1996) Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog. J Pharm Sci 85:396–401PubMedCrossRefGoogle Scholar
  68. 68.
    Slevin ML, Piall EM, Johnston A, Levison DA, Aherne GW, Tree SB, Lister TA (1984) The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension. Invest New Drugs 2:271–276PubMedCrossRefGoogle Scholar
  69. 69.
    Titulaer HA, Zuidema J, Kager PA, Wetsteyn JC, Lugt CB, Merkus FW (1990) The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J Pharm Pharmacol 42:810–813PubMedCrossRefGoogle Scholar
  70. 70.
    Chang HC, Li LC, Marsh KC, Tian Y, Grischeau D (1999) Parenteral sustained-release dosage forms of butorphanol for dogs. Int J Pharm 176:147–156CrossRefGoogle Scholar
  71. 71.
    Coleman MD, Mihaly GW, Ward SA, Edwards G, Howells RE, Breckenridge AM (1985) The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice. J Pharm Pharmacol 37:878–883PubMedCrossRefGoogle Scholar
  72. 72.
    Dova SW, Albarellos G, Kreil V, Montoya L, Ambros L, Hallu R, Rebuelto M (2008) Comparative pharmacokinetics of an injectable cephalexin suspension in beef cattle. Res Vet Sci 85:570–574CrossRefGoogle Scholar
  73. 73.
    Gido C, Langguth P, Kreuter J, Winter G, Woog H, Mutschler E (1993) Conventional versus novel conditions for the in vitro dissolution testing of parenteral slow release formulations: application to doxepin parenteral dosage forms. Pharmazie 48:764–769PubMedGoogle Scholar
  74. 74.
    Gido C, Langguth P, Mutschler E (1994) Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs. Pharm Res 11:800–808PubMedCrossRefGoogle Scholar
  75. 75.
    Liu KS, Hu OY, Ho ST, Tzeng JI, Chen YW, Wang JJ (2004) Antinociceptive effect of a novel long acting nalbuphine preparation. Br J Anaesth 92:712–715PubMedCrossRefGoogle Scholar
  76. 76.
    Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ (2006) Novel depots of buprenorphine prodrugs have a long acting antinociceptive effect. Anesth Analg 102:1445–1451PubMedCrossRefGoogle Scholar
  77. 77.
    Macgregor TR, Drum MA, Harrigan SE, Wiley JN, Reuning RH (1983) Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs. J Pharm Pharmacol 35:38–42PubMedCrossRefGoogle Scholar
  78. 78.
    Pecoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G, Abdou A, Etienne J, Rey M (1991) Long acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet 338:862–866PubMedCrossRefGoogle Scholar
  79. 79.
    Preechagoon D, Smith MT, Prankerd RJ (1998) Investigation of the antinociceptive efficacy and relative potency of extended duration injectable 3-acylmorphine-6-sulfate prodrugs in rats. Int J Pharm 163:191–201CrossRefGoogle Scholar
  80. 80.
    Timmins P, Cosgrove RF, Delargy AM (1986) Effect of a surfactant on absorption of an antibiotic from nonaqueous parenteral suspensions. Drug Dev Ind Pharm 12:829–837CrossRefGoogle Scholar
  81. 81.
    Madan PL (1985) Sustained-release drug delivery systems: part V, parenteral products. Pharm Manuf: 51–57Google Scholar
  82. 82.
    Crommelin DJA, Deblaey CJ (1980) In vitro release studies on drugs suspended in non-polar media I. Release of sodium-chloride from suspensions in liquid paraffin. Int J Pharm 5:305–316CrossRefGoogle Scholar
  83. 83.
    Crommelin DJA, Deblaey CJ (1980) In vitro release studies on drugs suspended in non-polar media II. The release of paracetamol and chloramphenicol from suspensions in liquid paraffin. Int J Pharm 6:29–42CrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2012

Authors and Affiliations

  • Susan W. Larsen
    • 1
  • Mette A. Thing
    • 1
  • Claus Larsen
    • 1
  1. 1.Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations